MicroStrategy sold 32 Bitcoin worth about $2.5 million between May 26 and May 31, 2026, its first sale since December 2022. This triggered a $20 million dispute on Polymarket, a crypto prediction market, over whether the sale counts as occurring by May 31 or only when publicly disclosed on June 1. Polymarket's resolution system escalated the dispute to a vote, highlighting challenges in aligning corporate disclosure rules with real-time market assumptions. The sale is minor relative to MicroStrategy's 843,706 BTC holdings and seen as routine treasury management, not a strategic shift.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
